首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1567156

慢性疼痛市場：按藥物類別、按適應症、按應用、按分銷管道、按地區

Chronic Pain Market, By Drug Class (Opioids, Non-steroidal anti-inflammatory drugs, Anticonvulsants, Antidepressants, and Others), By Indication, By Application, By Distribution Channel, By Geography

出版日期: 2024年08月27日 | 出版商:

Coherent Market Insights | 英文 260 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球慢性疼痛市場規模將達721億美元，預計2031年將達到1,155.1億美元，2024年至2031年複合年成長率為7%。

報告範圍		報告詳情
基準年	2023年	2024年市場規模	721億美元
實際資料	2019-2023	預測期	2024年至2031年
預測 2024-2031 年複合年成長率：	7.00%	2031年價值預測	1155.1億美元

圖：2024 年按地區分類的慢性疼痛市場佔有率(%)

慢性疼痛被定義為持續超過 3 個月或超過正常癒合期的疼痛。有許多疾病會導致慢性疼痛，包括關節炎、下背痛、癌症、神經系統疾病和纖維肌痛。久坐的生活方式和慢性疾病的增加可能會增加全球慢性疼痛的盛行率。慢性疼痛會限制活動能力和日常功能，對生活品質產生負面影響。全球慢性疼痛市場包括疼痛管理藥物、神經調節裝置和其他可緩解和改善患者預後的治療方式。容易受到這種情況影響的老齡化人口的快速成長、醫療保健支出的增加、新產品的推出以及對管理選擇的認知的提高正在推動市場的成長。

市場動態：

慢性疾病和傷害的日益流行在很大程度上導致了全球慢性疼痛發病率的上升。這包括肌肉骨骼疾病，例如骨關節炎和下背痛。老年人口的增加（更容易患此類疾病）將推動市場成長。此外，不斷成長的醫療保健支出、新產品創新以及支付昂貴治療方案的能力也將推動市場成長。然而，學名藥等替代品的存在、用藥違規以及某些治療方法的副作用可能會給市場參與者帶來挑戰。此外，新產品核可的監管障礙也可能阻礙市場成長。新興國家為產業參與者提供了龐大的商機。疼痛治療方法的技術進步可能為市場成長開闢新的途徑。

本研究的主要特點

該報告對全球慢性疼痛市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。

它還揭示了各個細分市場的潛在商機，並說明了該市場有吸引力的投資提案矩陣。

它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。

根據公司亮點、產品系列、主要亮點、業績和策略等參數對全球慢性疼痛市場的主要企業進行了分析。

研究涵蓋的主要企業包括輝瑞、禮來、GlaxoSmithKline Plc、諾華、強生、Astra Zeneca、普渡製藥、遠藤製藥、梯瓦製藥工業有限公司和 Mallinckrodt 製藥。

該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

全球慢性疼痛市場報告迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

透過用於分析全球慢性疼痛市場的各種策略矩陣，將有助於相關人員做出決策。

Pfizer Inc.
Johnson & Johnson
GlaxoSmithKline PLC
Bayer AG
Novartis AG
Endo Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Reckitt Benckiser Group plc
Medtronic plc
AstraZeneca PLC
Becton, Dickinson and Company
AbbVie Inc.
Horizon Therapeutics
Mallinckrodt Pharmaceuticals
Zynerba Pharmaceuticals
Neurocrine Biosciences
Sorrento Therapeutics
Cypress Pharmaceutical

第10章分析師建議

第11章參考文獻與調查方法

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI4767

Global chronic pain market is estimated to be valued at USD 72.10 Bn in 2024 and is expected to reach USD 115.51 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 72.10 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	7.00%	2031 Value Projection:	US$ 115.51 Bn

Figure. Chronic Pain Market Share (%), By Region, 2024

Chronic pain is defined as any pain lasting for more than three months or past the normal time of healing. The conditions that cause chronic pain are numerous and wide-ranging from arthritis, back pain, cancer, neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain market consists of drugs for pain management, neuromodulation devices, and other treatment modalities that provide relief and improve patient outcomes. Rapid growth in geriatric population who are more prone to such conditions, rise in healthcare expenditure, new product launches, and increasing awareness about management options can drive the market growth.

Market Dynamics:

Increasing prevalence of chronic diseases and injuries has significantly contributed to rising incidence of chronic pain worldwide. These include musculoskeletal disorders like osteoarthritis and lower back pain. Growing geriatric population who are more susceptible to such conditions can drive the market growth. Furthermore, greater healthcare spending, new product innovations, and ability to pay for expensive treatment options can also drive the market growth. However, presence of alternatives like generic drugs, non-compliance to medications, and side effects of certain therapies can pose challenges to market players. Moreover, regulatory hurdles for new product approvals can also hamper the market growth. Emerging economies provide major opportunities for industry players. Technological advancements in pain treatment modalities can open new avenues for the market growth.

Key features of the study:

This report provides in-depth analysis of the global chronic pain market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic pain market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer, Eli Lilly, GlaxoSmithKline, Novartis, Johnson & Johnson, AstraZeneca, Purdue Pharma, Endo Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., and Mallinckrodt Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic pain market

Detailed Segmentation-

By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
- Opioids
- Non-steroidal anti-inflammatory drugs (NSAIDS)
- Anticonvulsants
- Antidepressants
- Others
By Indication Insights (Revenue, USD Bn, 2019 - 2031)
- Neuropathic pain
- Arthritis pain
- Chronic back pain
- Cancer pain
- Migraine
- Fibromyalgia
- Others
By Application Insights (Revenue, USD Bn, 2019 - 2031)
- Musculoskeletal
- Neuropathy
- Oncology
- Others
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline PLC
- Bayer AG
- Novartis AG
- Endo Pharmaceuticals
- Bristol-Myers Squibb
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Reckitt Benckiser Group plc
- Medtronic plc
- AstraZeneca PLC
- Becton, Dickinson and Company
- AbbVie Inc.
- Horizon Therapeutics
- Mallinckrodt Pharmaceuticals
- Zynerba Pharmaceuticals
- Neurocrine Biosciences
- Sorrento Therapeutics
- Cypress Pharmaceutical

1. RESEARCH OBJECTIVES AND ASSUMPTIONS

Research Objectives
Assumptions
Abbreviations

2. MARKET PURVIEW

Report Description
- Market Definition and Scope
Executive Summary
- Global Chronic Pain Market, By Drug Class
- Global Chronic Pain Market, By Indication
- Global Chronic Pain Market, By Application
- Global Chronic Pain Market, By Distribution Channel
- Global Chronic Pain Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Chronic Pain Market, By Drug Class, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Non-steroidal anti-inflammatory drugs (NSAIDS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Chronic Pain Market, By Indication, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Neuropathic pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Arthritis pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Chronic back pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Cancer pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Migraine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Fibromyalgia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Chronic Pain Market, By Application, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Musculoskeletal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Chronic Pain Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Chronic Pain Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Application, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson
GlaxoSmithKline PLC
Bayer AG
Novartis AG
Endo Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Reckitt Benckiser Group plc
Medtronic plc
AstraZeneca PLC
Becton, Dickinson and Company
AbbVie Inc.
Horizon Therapeutics
Mallinckrodt Pharmaceuticals
Zynerba Pharmaceuticals
Neurocrine Biosciences
Sorrento Therapeutics
Cypress Pharmaceutical